Cargando…
Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant
Cytomegalovirus (CMV) reactivation is one of the most common infections affecting allogeneic hematopoietic cell transplant recipients. Although available anti-CMV therapies have been evaluated for the prevention of CMV reactivation, their toxicity profile makes them unfavorable for use as primary pr...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318821/ https://www.ncbi.nlm.nih.gov/pubmed/32637057 http://dx.doi.org/10.1177/2040620720937150 |
_version_ | 1783550937955041280 |
---|---|
author | Shigle, Terri Lynn Handy, Victoria Wehr Chemaly, Roy F. |
author_facet | Shigle, Terri Lynn Handy, Victoria Wehr Chemaly, Roy F. |
author_sort | Shigle, Terri Lynn |
collection | PubMed |
description | Cytomegalovirus (CMV) reactivation is one of the most common infections affecting allogeneic hematopoietic cell transplant recipients. Although available anti-CMV therapies have been evaluated for the prevention of CMV reactivation, their toxicity profile makes them unfavorable for use as primary prophylaxis; thus, they are routinely reserved for the treatment of CMV viremia or CMV end-organ disease. Pre-emptive CMV monitoring strategies have been widely accepted, and although they have been helpful in early detection, they have not affected the overall morbidity and mortality associated with CMV. Letermovir is a novel agent that was approved for primary prophylaxis in CMV-seropositive adult allogeneic hematopoietic cell transplant recipients. This review focuses on letermovir’s novel mechanism; clinical trials supporting its United States Food and Drug Administration (FDA) approval and subsequent follow-up analyses; clinical considerations, with an emphasis on pharmacology; and lessons learned from solid organ transplant recipients, as well as potential future directions. |
format | Online Article Text |
id | pubmed-7318821 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-73188212020-07-06 Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant Shigle, Terri Lynn Handy, Victoria Wehr Chemaly, Roy F. Ther Adv Hematol Review Cytomegalovirus (CMV) reactivation is one of the most common infections affecting allogeneic hematopoietic cell transplant recipients. Although available anti-CMV therapies have been evaluated for the prevention of CMV reactivation, their toxicity profile makes them unfavorable for use as primary prophylaxis; thus, they are routinely reserved for the treatment of CMV viremia or CMV end-organ disease. Pre-emptive CMV monitoring strategies have been widely accepted, and although they have been helpful in early detection, they have not affected the overall morbidity and mortality associated with CMV. Letermovir is a novel agent that was approved for primary prophylaxis in CMV-seropositive adult allogeneic hematopoietic cell transplant recipients. This review focuses on letermovir’s novel mechanism; clinical trials supporting its United States Food and Drug Administration (FDA) approval and subsequent follow-up analyses; clinical considerations, with an emphasis on pharmacology; and lessons learned from solid organ transplant recipients, as well as potential future directions. SAGE Publications 2020-06-24 /pmc/articles/PMC7318821/ /pubmed/32637057 http://dx.doi.org/10.1177/2040620720937150 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Shigle, Terri Lynn Handy, Victoria Wehr Chemaly, Roy F. Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant |
title | Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant |
title_full | Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant |
title_fullStr | Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant |
title_full_unstemmed | Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant |
title_short | Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant |
title_sort | letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318821/ https://www.ncbi.nlm.nih.gov/pubmed/32637057 http://dx.doi.org/10.1177/2040620720937150 |
work_keys_str_mv | AT shigleterrilynn letermoviranditsroleinthepreventionofcytomegalovirusinfectioninseropositivepatientsreceivinganallogeneichematopoieticcelltransplant AT handyvictoriawehr letermoviranditsroleinthepreventionofcytomegalovirusinfectioninseropositivepatientsreceivinganallogeneichematopoieticcelltransplant AT chemalyroyf letermoviranditsroleinthepreventionofcytomegalovirusinfectioninseropositivepatientsreceivinganallogeneichematopoieticcelltransplant |